自体TIL治疗癌性胸水的临床疗效观察  

The Clinical Effects on Malignant Pleural Effusion with Self TIL Adoptive Immunity Therapy

作　　者：张新[1] 李菁[1] 贾友明[1] 韩葆惠 白春学[1] 

机构地区：[1]上海医科大学呼吸病研究所,200032

出　　处：《中国临床医学杂志》2000年第2期180-181,共2页

摘　　要：目的：研究自体肿瘤浸润淋巴细胞合并重组白细胞介素－２（ＴＩＬ／ｒＩＬ－２）过继免疫疗法对癌性胸腔积液的临床疗效。方法：对１９９３年１０月～１９９８年１２月的４６例癌性胸腔积液患者，行胸水ＴＩＬ体外扩增并自体回输，观察近期和远期疗效。结果：在可评价疗效的 ４４例患者中，２０例完全缓解（４５． ５％）， １１例部分缓解（２５． ０％）， １３例无效（２９ ．５％），总有效率７０． ５％。完全缓解的病例随访中均未见治疗侧胸腔积液复发。结论：自体 ＴＩＬ／ｒＩＬ— ２过继免疫治疗癌性胸水有良好的临床应用价值。Objective: To study the clinical effects on malignant pleural effusion with self tumor infiltrating lymphocytes combined with recombinant interleukin - 2 (TIL/rIL - 2). Materials and Methods: 46 patients suffering from malignant pleural fluid were treated with self - transfusion of TIL after amplification in vitro. The immediate and long - term effects were observed. Results: The effects in the 44 cases of pleural fluid could be assessed, 20 (45. 5 % ) cases were CR, 11 (25. 0 % ) cases were PR and 13 (29. 5 % ) were NR. The total effective rate was 70. 5 %. No recurrence of hydrothorax in treated cases was observed in the follow up of CR. Conclusion: The adoptive immunity therapy with self TIL/rIL - 2 is valuable to treat malignant pleural effusion.

关 键 词：癌性胸腔积液 过继免疫疗法 自体TIL 

分 类 号：R730.51[医药卫生—肿瘤] R561.305[医药卫生—临床医学]